NCT06189066Completed
Long COVID Ultrasound Trial
Long COVID Ultrasound Trial [LOCUS Trial]
Source: ClinicalTrials.gov · Last updated 7 Jan 2026
Brief summary (registry, in English)
The research objective is to assess the safety and potential efficacy of spleen ultrasound stimulation as an intervention for Long COVID in a pilot study. Specific Aims include: * Measure Long COVID disease activity before, during and after an 8-week course of spleen-directed daily ultrasound stimulation. * Measure molecular correlates of Long COVID disease activity before, during and after an 8-week course of spleen-directed daily ultrasound stimulation. * Track adverse events throughout the study to assess safety of the ultrasound intervention.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 15 (actual)
- First submitted
- 31 Dec 2023
- Start date
- 3 Jan 2024
- Primary completion date
- 24 Jul 2024
- Lead sponsor
- SecondWave Systems Inc.
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT06189066
What you commit to
- Study type: Interventional
- Participants enrolled: 15
- From 3 Jan 2024 to the primary completion date, 24 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Candidate that is currently taking immune modifying medications and unable to maintain stable levels of their immune medication regimen throughout the study period
- Prior history of Lyme disease
- Prior history cognitive impairment
- Any non-marijuana drug abuse history within 30 days
- Current use of an investigational drug
- History of prior myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS)
- Prior history of postural orthostatic tachycardia syndrome (POTS)
- History of prior chronic pain
Other illness
- Candidate who is unable or unwilling to postpone taking new medications used for treating Long COVID during the study period
- History of intubation secondary to COVID-19
- ICU admission for COVID-19
- Pre-existing Lung conditions such as chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), or severe asthma
- History of coronary artery disease (CAD)
- History of stroke
- History of alcohol abuse: greater than 2 drinks a day for men and 1 drink for females
- Chronic fatigue secondary to any condition other than COVID-19.
- History of chronic liver disease such as cirrhosis
- History of splenic pathology such as spleen infarct/splenomegaly
- History of splenectomy
- History of Sickle disease with splenic pathology
- Taking non-approved treatments for Long COVID
Lab values
- History of severe anemia of hemoglobin less than 8 g/dl
Other
- Pregnant
- Fibromyalgia
- Participant does not speak English
- Participant is an active member of the military (service member) or DoD personnel (including civilian employees)
- Any other clinical reasons deemed by the investigators of the study in which the patient would not be an appropriate candidate for the study
Who the study is looking for
- Age 18-65 years at the time of enrollment
- Prior diagnosis of COVID-19 by report, PCR, or home kit
- Symptoms present for 12 or more weeks that are independent prior to SARS-CoV-2 infection including fatigue and one or more of:
- Myalgia or general aches/pains
- Joint pain
- Dizziness/lightheadedness
- Cognitive dysfunction (brain fog)
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Minnesota - Phillips-Wangensteen Building Coordinator of this site? Confirm its status | Minneapolis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.